Restless legs syndrome in children: A review and update on pharmacological options

Current Pharmaceutical Design

Volumn 17, Issue 15, 2011, Pages 1436-1442

  Frenette, Eric ^a  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

Author keywords

Augmentation; Dopamine agonist; Ferritin; Genetics; Pediatric; Restless legs syndrome; Rls; Treatment

Indexed keywords

AMANTADINE; ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; BROMOCRIPTINE; CABERGOLINE; CARBAMAZEPINE; CLONAZEPAM; CLONIDINE; DIHYDROERGOCRYPTINE; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; GABAPENTIN; GABAPENTIN ENACARBIL; IRON; LEVODOPA; LISURIDE; METHADONE; OPIATE; OXYCODONE; PERGOLIDE; PRAMIPEXOLE; PREGABALIN; ROPINIROLE; ROTIGOTINE; SUMANIROLE; TOPIRAMATE; TRAMADOL; UNINDEXED DRUG; VALPROIC ACID; ZOLPIDEM;

APPLICATION SITE REACTION; ARTICLE; ATTENTION DEFICIT DISORDER; AUTOSOMAL DOMINANT INHERITANCE; AUTOSOMAL RECESSIVE INHERITANCE; BEHAVIOR THERAPY; CHILD; CHILDHOOD; CIRCADIAN RHYTHM; COMORBIDITY; DIFFERENTIAL DIAGNOSIS; DIZZINESS; DOPAMINE METABOLISM; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG TISSUE LEVEL; FOOD; FOOD AND DRUG ADMINISTRATION; FOOD DRUG INTERACTION; GENE LOCUS; GENETIC LINKAGE; GROUPS BY AGE; HEADACHE; HUMAN; IRON DEFICIENCY; IRON METABOLISM; IRON THERAPY; NAUSEA; PATHOPHYSIOLOGY; PERIPHERAL EDEMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTLESS LEGS SYNDROME; SOMNOLENCE; UNPLEASANT SENSATION;

ADULT; AGE FACTORS; ANIMALS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; DIAGNOSIS, DIFFERENTIAL; HUMANS; IRON; RESTLESS LEGS SYNDROME;

EID: 84856254541     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211796197142     Document Type: Article

References (51)

1. Ekbom K, Ulfberg J. Restless legs syndrome. J Intern Med 2009; 266: 419-31.
2. Hening W, Walters AS, Allen RP, Montplaisir J, Myers A, Ferini- Strambi L. Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study. Sleep Med 2004; 5: 237-46.
3. Montplaisir J, Boucher S, Poirier G, Lavigne G, Lapierre O, Lesperance P. Clinical, polysomnographic, and genetic characteristics of restless legs syndrome: a study of 133 patients diagnosed with new standard criteria. Mov Disord 1997; 12: 61-5
4. Walters AS, Picchietti DL, Ehrenberg BL, Wagner ML. Restless legs syndrome in childhood and adolescence. Pediatr Neurol 1994; 11: 241-5.
5. Picchietti D, Allen RP, Walters AS, Davidson JE, Myers A, Ferini- Strambi L. Restless legs syndrome: prevalence and impact in children and adolescents - the Peds REST study. Pediatrics 2007; 120: 253-66.
6. Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters AS, Montplaisir J. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the national institutes of health. Sleep Med 2003; 4: 101-19.
7. Picchietti MA, Picchietti DL. Advances in pediatric restless legs syndrome: Iron, genetics, diagnosis and treatment. Sleep Med 2010; 11: 643-51.
8. Allen RP, Earley CJ. Defining the phenotype of the restless legs syndrome (RLS) using age-of-symptom-onset. Sleep Med 2000; 1: 11-9.
9. Picchietti DL, Stevens HE. Early manifestations of restless legs syndrome in childhood and adolescence. Sleep Med 2008; 9: 770-81.
10. Trenkwalder C, Paulus W. Restless legs syndrome: pathophysiology, clinical presentation and management. Nat Rev Neurol 2010; 6: 337-46.
11. Lavigne GJ, Montplaisir JY. Restless legs syndrome and sleep bruxism: prevalence and association among Canadians. Sleep 1994; 17: 739-43.
12. Desautels A, Turecki G, Montplaisir J, Sequeira A, Verner A, Rouleau GA. Identification of a major susceptibility locus for restless legs syndrome on chromosome 12q. Am J Hum Genet 2001; 69: 1266-70.
13. Desautels A, Turecki G, Montplaisir J, et al. Restless legs syndrome: confirmation of linkage to chromosome 12q, genetic heterogeneity, and evidence of complexity. Arch Neurol 2005; 62: 591-6.
14. Winkelmann J, Lichtner P, Pütz B, et al. Evidence for further genetic locus heterogeneity and confirmation of RLS-1 in restless legs syndrome. Mov Disord 2006; 21: 28-33.
15. Levchenko A, Montplaisir J, Dubé M, et al. The 14q restless legs syndrome locus in the French Canadian population. Ann Neurol 2004; 55: 887-91.
16. Bonati MT, Ferini-Strambi L, Aridon P, Oldani A, Zucconi M, Casari G. Autosomal dominant restless legs syndrome maps on chromosome 14q. Brain 2003; 126: 1485-92.
17. Liebetanz KM, Winkelmann J, Trenkwalder C, et al. RLS3: finemapping of an autosomal dominant locus in a family with intrafamilial heterogeneity. Neurology 2006; 67: 320-21.
18. Lohmann-Hedrich K, Neumann A, Kleensang A, et al. Evidence for linkage of restless legs syndrome to chromosome 9p: are there two distinct loci? Neurology 2008; 70: 686-94.
19. Levchenko A, Provost S, Montplaisir JY, et al. A novel autosomal dominant restless legs syndrome locus maps to chromosome 20p13. Neurology 2006; 67: 900-01.
20. Pichler I, Marroni F, Volpato CB, et al. Linkage analysis identifies a novel locus for restless legs syndrome on chromosome 2q in a South Tyrolean population isolate. Neurology 2006; 79: 716-23.
21. Levchenko, A. Autosomal-dominant locus for restless legs syndrome in French-Canadians on chromosome 16p12.1. MovDisord24 (2008): 40-50.
22. Winkelmann J, Schormair B, Lichtner P, et al. Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions. Nat Genet; 2006; 39: 1000-6.
23. Schormair B, Kemlink D, Roeske D, et al. PTPRD (protein tyrosine phosphatase receptor type delta) is associated with restless legs syndrome. Nat Genet 2008; 40: 946-8.
24. Stefansson H, Rye DB, Hicks A, et al. A genetic risk factor for periodic limb movements in sleep. N Engl J Med 2007; 357: 639-47.
25. Salas RE, Gamaldo CE, Allen RP. Update in restless legs syndrome. Curr Opin Neurol 2010; 23: 401-6.
26. García-Borreguero D, Allen RP, Kohnen R, et al.; International Restless Legs Syndrome Study Group. Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute. Sleep Med 2007; 8: 520-30.
27. Williams AM, Garcia-Borreguero D. Management of restless legs syndrome augmentation. Curr Treat Options Neurol 2009; 11: 327-32.
28. Lesage S, Earley CJ. Restless Legs Syndrome. Curr Treat Options Neurol 2004; 6: 209-19.
29. Picchietti MA, Picchietti DL. Restless legs syndrome and periodic limb movement disorder in children and adolescents. Semin Pediatr Neurol 2008; 15: 91-9.
30. Earley CJ, Horska A, Mohamed MA, Barker PB, Beard JL, Allen RP. A randomized, double-blind, placebo-controlled trial of intravenous iron sucrose in restless legs syndrome. Sleep Med 2009; 10: 206-11.
31. Grote L, Leissner L, Hedner J, Ulfberg J. A randomized, doubleblind, placebo controlled, multi-center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome. Mov Disord 2009; 24: 1445-52.
32. Allen RP, Butcher A, Du W. Double-blind, placebo-controlled multicenter evaluation of restless legs syndrome treatment with 1000 mg of IV iron (ferric carboxymaltose). Sleep 2009; 32: A294-5.
33. Davis BJ, Rajput A, Rajput ML, Aul EA, Eichhorn GR. A randomized, doubleblind placebo-controlled trial of iron in restless legs syndrome. Eur Neurol 2000; 43: 70-5.
34. Wang J, O'Reilly B, Venkataraman R, Mysliwiec V, Mysliwiec A. Efficacy of oral iron in patients with restless legs syndrome and a low-normal ferritin: a randomized, double-blind, placebocontrolled study. Sleep Med 2009; 10: 973-5.
35. Trenkwalder C, Hening WA, Montagna P, et al. Treatment of restless legs syndrome: an evidence-based review and implications for clinical practice. Mov Disord 2008; 23: 2267-302.
36. Pelayo R, Dubik M. Pediatric sleep pharmacology. Semin Pediatr Neurol 2008; 15: 79-90.
37. US Food and Drug Administration [Home Page for the Food and Drug Administration (FDA)]. Silver Spring, MD. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/017555s070 lbl.pdf. Accessed 03/11/2011.
38. US Food and Drug Administration [Home Page for the Food and Drug Administration (FDA)]. Silver Spring, MD. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019856s027 lbl.pdf. Accessed 03/11/2011.
39. US Food and Drug Administration [Home Page for the Food and Drug Administration (FDA)]. Silver Spring, MD. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020667s014s017s018lbl.pdf. Accessed 03/14/2011.
40. US Food and Drug Administration [Home Page for the Food and Drug Administration (FDA)]. Silver Spring, MD. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020658s018s020s021lbl.pdf. Accessed 03/14/2011.
41. Serafini A, Lorenzut S, Gigli GL, Merlino G, Valente M. The use of rotigotine in the treatment of restless legs syndrome. Ther Adv Neurol Disord 2010; 3: 241-8.
42. Simakajornboon N, Kheirandish-Gozal L, Gozal D. Diagnosis and management of restless legs syndrome in children. Sleep Med Rev 2009 Apr; 13(2): 149-56.
43. US Food and Drug Administration [Home Page for the Food and Drug Administration (FDA)]. Silver Spring, MD. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020235s036,020882s022,021129s022lbl.pdf. Accessed 03/12/2011.
44. Yaltho TC, Ondo WG. The use of gabapentin enacarbil in the treatment of restless legs syndrome. Ther Adv Neurol Disord 2010; 3: 269-75.
45. US Food and Drug Administration [Home Page for the Food and Drug Administration (FDA)]. Silver Spring, MD. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021446s021lbl.pdf. Accessed 03/10/2011.
46. US Food and Drug Administration [Home Page for the Food and Drug Administration (FDA)]. Silver Spring, MD. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022272s006lbl.pdf. Accessed 03/15/2011.
47. US Food and Drug Administration [Home Page for the Food and Drug Administration (FDA)]. Silver Spring, MD. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/017058s019lbl.pdf. Accessed 03/15/2011.
48. US Food and Drug Administration [Home Page for the Food and Drug Administration (FDA)]. Silver Spring, MD. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022370s000lbl.pdf. Accessed 03/15/2011.
49. US Food and Drug Administration [Home Page for the Food and Drug Administration (FDA)]. Silver Spring, MD. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/017407s036lbl.pdf. Accessed 03/12/2011.
50. US Food and Drug Administration [Home Page for the Food and Drug Administration (FDA)]. Silver Spring, MD. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/017533s046s048,020813s006s007lbl.pdf. Accessed 03/12/2011.
51. US Food and Drug Administration [Home Page for the Food and Drug Administration (FDA)]. Silver Spring, MD. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019908s029lbl.pdf. Accessed 03/12/2011.